Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer

International Journal of Gynecological Cancer

Volumn 19, Issue 6, 2009, Pages 1022-1028

  Nicoletto, Maria Ornella ^a   Bertorelle, Roberta ^a   Borgato, Lucia ^a   De Salvo, Gian Luca ^a   Artioli, Grazia ^a   Lombardi, Giuseppe ^a   Zustovich, Fable ^a   Marcato, Raffaella ^a   Parenti, Anna ^b   Montagna, Marco ^a   Donach, Martin E ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

BRCA; Ovarian cancer; Oxaliplatin; P53; PLD

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DEXAMETHASONE; DOXORUBICIN; GRANISETRON; OXALIPLATIN; PLATINUM; PROTEIN P53;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DOXORUBICIN; FAMILY HEALTH; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 70349244795     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a83cb5     Document Type: Article

References (34)

1. Dizon DS, Hensley ML, Poynor EA, et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol. 2002;20:1238-1247.
2. Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22:3120-3125.
3. van der Burg ME, van der Gaast A, Vergote I, et al. What is the role of dose-dense therapy? Int J Gynecol Cancer. 2005;15:233-240.
4. Gore ME, Fryatt I,Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;36:207-211. (Pubitemid 20061287)
5. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/ AGO-OVAR-2.2 trial. Lancet. 2003;361:2099-2106.
6. A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol. 1995;13:726-732.
7. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1-8.
8. Nicoletto MO, Falci C, Pianalto D, et al. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol Oncol. 2006;100:318-323.
9. Viens P, Petit T, Yovine A, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol. 2006;17:429-436.
10. Santos AM, Sousa H, Portela C, et al. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun. 2006;340:256-262.
11. Lavarino C, Pilotti S, Oggionni M, et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol. 2000;18:3936-3945.
12. Bar JK, Harlozinska A, Popiela A, et al. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy. Tumour Biol. 2001;22: 83-91.
13. Protopapas A, Diakomanolis E, Bamias A, et al. The prognostic significance of the immunohistochemical expression of p53, bcl-2, cerb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy. Eur J Gynaecol Oncol. 2004;25:225-229.
14. Cassinelli G, Supino R, Perego P, et al. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer. 2001;92:738-747.
15. de la Torre FJ, Garcia A, Gil-Moreno A, et al. Apoptosis in epithelial ovarian tumours prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax). Eur J Obstet Gynecol Reprod Biol. 2007;130:121-128.
16. Reles A,Wen WH, Schmider A, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 2001;7:2984-2997.
17. Skirnisdottir I, Seidal T, Gerdin E, et al. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer. 2002;12:265-276.
18. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97:2187-2195.
19. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer. 2006;5:135-142.
20. Reedy MB, Hang T, Gallion H, et al. Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis. Gynecol Oncol. 2001;81: 441-446.
21. Prat J, Ribe A, Gallardo A. Hereditary ovarian cancer. Hum Pathol. 2005;36:861-870.
22. Zweemer RP, Shaw PA, Verheijen RM, et al. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J Clin Pathol. 1999;52:372-375.
23. Bertorelle R, Esposito G, Del Mistro A, et al. Association of p53 gene and protein alterations with metastases in colorectal cancer. Am J Surg Pathol. 1995;19:463-471.
24. Agata S, Viel A, Della Puppa L. Prevalence of BRCA1, genomic rearrangements in a large cohort of Italian breast and breast/ovarian families without detectable BRCA1 and BRCA2 point mutations. Genes Chromosomes Cancer. 2006;45:791-797.
25. Montagna M, Dalla Palma M, Menin C, et al. Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum Mol Genet. 2003;12: 1055-1061.
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of theUnited States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
27. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol. 2003;21:187sY193s.
28. Pharoah P. Practical applications of genetics and epidemiology. In: Ghaem-Maghami S, Orton K, Soutter P, eds. Key Advances in the Clinical Management of Ovarian Cancer. London, UK: Royal Society of Medicine Press Ltd; 2003:9-14.
29. Havrilesky L, Darcy M, Hamdan HJ, et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2003;21:3814-3825.
30. Ueno Y, Enomoto T, Otsuki Y, et al. Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. Cancer Lett. 2006;241:289-300.
31. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283: 2260-2265.
32. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007;8:735-748.
33. Turner N, Tutt A, Ashworth A. Hallmarks of FBRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4:814-819.
34. Ferrero JM, Weber B, Geay JF, et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol. 2007;18:263-268.